

No.	Sex	Age	IHC/FISH	NGS (tier I variants, genes)	Symptoms	Site of involvement at diagnosis	AA stage	Treatment regimen	Best response	CNS relapse	Status at last follow-up
1	M	74	Non-GCB	U/K	Nasal symptoms: nasal obstruction, rhinorrhoea Eye symptoms: periorbital swelling, periorbital pain, epiphora, diplopia Facial symptoms: facial swelling, facial pain	Nasal cavity, paranasal sinuses	IVA	R-CHOP R-HD-MTX	CR	Yes	PFS: 9.83 months OS: 17.00 months Outcome: died of CNS relapse
2	F	62	Non-GCB Triple expression EBER (-) No MYC rearrangements	MYD88 CD79B KMT2D B2M CREBBP TP53	Facial symptoms: facial swelling, facial pain	Paranasal sinuses, lymph node, CNS	IVA	R-MTX-CHOP	CR	Yes	PFS: 20.37 months OS: 20.37 months Outcome: died of CNS relapse
3	F	59	GCB Triple expression EBER (-) No MYC rearrangements	MYD88 CD79B PIM1 KMT2C BTG1 IRF8	Eye symptoms: diplopia, blurred vision, limited eye movement	Paranasal sinuses, lymph node, bone marrow, CNS	IVB	R-MTX-DA-EPOCH plus Orelabrutinib	CR	No	PFS: 25.80 months OS: 25.80 months Outcome: alive with CR
4	M	61	GCB EBER (-) No MYC rearrangements	MYD88 CD79B PIM1 KMT2D EP300 BTG2 DTX1	Nasal symptoms: nasal obstruction, rhinorrhoea, epistaxis	Nasal cavity, paranasal sinuses, bone marrow	IVB	Pola-R-CHP R-HD-MTX Auto-HSCT Orelabrutinib	CR	No	PFS: 19.07 months OS: 19.07 months Outcome: alive with CR
5	M	56	Non-GCB EBER (-) No MYC rearrangements	MYD88 CD79B PIM1 KMT2C MPEG1 NOTCH1 PRDM1	Eye symptoms: periorbital swelling, periorbital pain, limited eye movement	Paranasal sinuses	IA	R-DA-EPOCH R-HD-MTX Orelabrutinib	CR	No	PFS: 20.87 months OS: 20.87 months Outcome: alive with CR

No.	Sex	Age	IHC/FISH	NGS (tier I variants, genes)	Symptoms	Site of involvement at diagnosis	AA stage	Treatment regimen	Best Response	CNS relapse	Status at last follow-up
6	F	66	Non-GCB Double expression EBER (-) MYC-IGH rearrangements	<i>MYD88</i> <i>CD79B</i> <i>NOTCH1</i> <i>CIITA</i>	Nasal symptoms: nasal obstruction, hyposmia	Nasal cavity	IA	R-DA-EPOCH R-HD-MTX	CR	No	PFS: 10.37 months OS: 10.37 months Outcome: alive with CR
7	M	61	GCB Triple expression EBER (-) No MYC rearrangements	<i>MYD88</i> <i>PIM1</i> <i>CCND3</i> <i>SGK1</i>	Nasal symptoms: nasal obstruction, rhinorrhoea, hyposmia Eye symptoms: periorbital swelling, periorbital pain	Nasal cavity, paranasal sinuses	IB	Pola-R-CHP R-HD-MTX	PR	No	PFS: 6.63 months OS: 6.63 months Outcome: alive with PR
8	M	66	GCB Triple expression EBER (-) No MYC rearrangements	<i>MYD88</i> <i>CD79B</i> <i>PIM1</i> <i>KMT2D</i> <i>EP300</i> <i>MPEG1</i> <i>TRAF3</i>	Nasal symptoms: nasal obstruction, epistaxis Eye symptoms: periorbital pain, periorbital swelling, diplopia	Nasal cavity, paranasal sinuses	IB	Pola-R-CHP	U/K	No	PFS: 4.33 months OS: 4.33 months Outcome: alive with disease

AA stage: Ann Arbor stage; auto-HSCT: autologous hematopoietic stem cell transplantation; CHOP: cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisolone; CNS: central nervous system; CR: complete remission; EBER: Epstein–Barr virus-encoded ribonucleic acid; F: female; FISH: fluorecence in situ hybridisation; GCB: germinal centre B-cell; IGH: immunoglobulin; IHC: immunohistochemistry; LN: lymph node; M: male; MTX: methotrexate; MYC: myelocytomatosis oncogene; NGS: next-generation sequencing; OS: overall survival; PFS: progression-free survival; PR: partial remission; Pola-R-CHP: polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone; R: rituximab; R-DA-EPOCH: dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab; R-HD-MTX: rituximab and high-dose methotrexate; U/K: unknown